Basal-like breast cancer and the BRCA1 phenotype
NC Turner, JS Reis-Filho - Oncogene, 2006 - nature.com
NC Turner, JS Reis-Filho
Oncogene, 2006•nature.comBreast cancers arising in germline carriers of BRCA1 mutations have a characteristic
phenotype that has been shown in many studies to differentiate BRCA1 tumours from
sporadic tumours. Recently, it has become clear that the characteristic phenotype of BRCA1
tumours is due to expression of the basal-like phenotype. We review these phenotypes, the
evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the
clinical significance of the basal-like phenotype for cancer genetics and treatment.
phenotype that has been shown in many studies to differentiate BRCA1 tumours from
sporadic tumours. Recently, it has become clear that the characteristic phenotype of BRCA1
tumours is due to expression of the basal-like phenotype. We review these phenotypes, the
evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the
clinical significance of the basal-like phenotype for cancer genetics and treatment.
Abstract
Breast cancers arising in germline carriers of BRCA1 mutations have a characteristic phenotype that has been shown in many studies to differentiate BRCA1 tumours from sporadic tumours. Recently, it has become clear that the characteristic phenotype of BRCA1 tumours is due to expression of the basal-like phenotype. We review these phenotypes, the evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the clinical significance of the basal-like phenotype for cancer genetics and treatment.
nature.com